Kim A. Reiss Binder, MD, discusses the initial results of a phase 1 trial, which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.
Kim A. Reiss Binder, MD, medical oncologist, assistant program director, Hematology/Oncology Fellowship Program, Abramson Cancer Center, Penn Medicine, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the initial results of a phase 1 trial (NCT04660929), which is evaluating CT-0508 in patients with HER2-overexpressing solid tumors.
CT-0508 is a cell product comprised of autologous peripheral blood monocyte–derived macrophages that are transduced with an adenoviral vector containing a HER2-directed CAR and locked into an M1 phenotype. The therapy is being evaluated in an ongoing phase 1 trial in patients with HER2-overexpressing solid tumors.
Initial results of 2 patients treated with CT-0508 were presented during the 2021 SITC Annual Meeting. Regarding safety, 1 patient developed grade 2 cytokine release syndrome (CRS) characterized by fever and hypotension on day 3. The toxicity was resolved on day 4 with acetaminophen (Tylenol), cefepime (Maxipime), and fluids. The other patient, as well as 1 patient who was treated on study but not included in the poster presentation, did not develop CRS with CT-0508.
Although further data are needed to determine whether this therapy is safe, patients treated with CT-0508 are unlikely to develop severe CRS based on the therapy’s mechanism of action, Reiss Binder concludes.